Prolymphocytic leukemia: Difference between revisions
Aditya Ganti (talk | contribs) |
|||
(8 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Prolymphocytic leukemia}} | ||
{{CMG}}; {{AE}} {{CLG}}, {{MV}} | {{CMG}}; {{AE}} {{CLG}}, {{MV}} | ||
Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
'''Prolymphocytic leukemia''' is a rare lymphoid leukemia, which account for only about 2% of all mature lymphoid leukemias. Prolymphocytic leukemias present similar to leukemia. Like lymphomas, they originate in the lymphocytes, but do not form solid tumors. Prolymphocytic leukemias are also considered lymphoproliferative disorders, which | '''Prolymphocytic leukemia''' is a rare [[lymphoid leukemia]], which account for only about 2% of all mature [[Lymphoid leukemia|lymphoid leukemias]]. Prolymphocytic leukemias present similar to [[leukemia]]. Like [[Lymphoma|lymphomas]], they originate in the [[Lymphocyte|lymphocytes]], but do not form solid [[Tumor|tumors]]. Prolymphocytic leukemias are also considered [[lymphoproliferative disorders]], which [[Lymphocyte|lymphocytes]] are produced in large amounts. Prolymphocytic leukemia may be classified according to the type of [[Cell (biology)|cell]] involved: [[B-cell prolymphocytic leukemia]] and [[T-cell prolymphocytic leukemia]]. Originally, it was thought to be a rare variation of [[chronic lymphocytic leukemia]], but is now considered a distinct disease. It is usually classified as a kind of [[chronic lymphocytic leukemia]]. Although these 2 types of prolymphocytic leukemias share some of the same characteristics, the [[World Health Organization]] (WHO) classifies them as different types of lymphoid leukemias.<ref name="PL">{{cite web | title = World Health Organization| url =http://search.who.int/search?q=acute+prolymphocytic+leukemia&ie=utf8&site=who&client=_en_r&proxystylesheet=_en_r&output=xml_no_dtd&oe=utf8&getfields=doctype }}</ref> | ||
Prolymphocytic leukemia may be classified according to the type of cell involved: [[B-cell prolymphocytic leukemia]] and [[T-cell prolymphocytic leukemia]]. Originally, it was thought to be a rare variation of chronic lymphocytic leukemia, but is now considered a distinct disease. It is usually classified as a kind of [[chronic lymphocytic leukemia]]. Although these 2 types of prolymphocytic leukemias share some of the same characteristics, the [[World Health Organization]] (WHO) classifies them as different types of lymphoid leukemias.<ref name="PL">{{cite web | title = World Health Organization| url =http://search.who.int/search?q=acute+prolymphocytic+leukemia&ie=utf8&site=who&client=_en_r&proxystylesheet=_en_r&output=xml_no_dtd&oe=utf8&getfields=doctype }}</ref> | |||
==Classification== | ==Classification== | ||
Line 15: | Line 13: | ||
{{Familytree/start}} | {{Familytree/start}} | ||
{{Familytree | {{Familytree | | | | | A01 | | | | | A01= '''Prolymphocytic leukemia'''}} | ||
{{Familytree | {{Familytree | |,|-|-|-|^|-|-|-|.| }} | ||
{{Familytree | {{Familytree | B01 | | | | | | B02 | B01= [[B-cell prolymphocytic leukemia]]|B02=[[T-cell prolymphocytic leukemia]]}} | ||
|B02= | |||
{{Familytree/end}} | {{Familytree/end}} | ||
Line 25: | Line 22: | ||
{| | {| | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Characteristics | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Characteristics | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B- | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |B-cell Prolymphocytic Leukemia | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |T- | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |T-cell Prolymphocytic Leukemia | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Epidemiology | ! align="center" style="background:#DCDCDC;" + |Epidemiology | ||
Line 72: | Line 69: | ||
Biomarkers | Biomarkers | ||
:*CD52+ | :*CD52+ | ||
|} | |||
== Differentiating Prolymphocytic Leukemia from other Leukemias == | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" | |||
| valign="top" | | |||
|- | |||
! style="background: #4479BA; width: 600px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|'''Surface Immunoglobulin'''}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|'''CD5'''}} | |||
! style="background: #4479BA; width: 400px;" |{{fontcolor|#FFF|'''CD22/FMC7'''}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|'''CD23'''}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|'''CD79b'''}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|'''CD103'''}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''Prolymphocytic leukaemia''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Strongly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''Hairy cell leukaemia''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Strongly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive/Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''Chronic lymphocytic leukaemia''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Weakly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive/Negative''' | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''Mantle cell lymphoma''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Strongly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Strongly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''Follicular lymphoma''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Strongly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Strongly positive''' | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |'''Negative''' | |||
|} | |||
{| | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | |||
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Manifestation | |||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Acute myelogenous leukemia]]<ref name="pmid30410824">{{cite journal |vauthors=Saif A, Kazmi SFA, Naseem R, Shah H, Butt MO |title=Acute Myeloid Leukemia: Is That All There Is? |journal=Cureus |volume=10 |issue=8 |pages=e3198 |date=August 2018 |pmid=30410824 |doi=10.7759/cureus.3198 |url=}}</ref><ref name="pmid23526416">{{cite journal |vauthors=Estey EH |title=Acute myeloid leukemia: 2013 update on risk-stratification and management |journal=Am. J. Hematol. |volume=88 |issue=4 |pages=318–27 |date=April 2013 |pmid=23526416 |doi=10.1002/ajh.23404 |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Clonal proliferation of malignant myeloid blast cells in the marrow | |||
* Genetic abnormalities t(8;21), inv(16), and t(15;17) | |||
| align="left" style="background:#F5F5F5;" + | | |||
* The most common leukemia in adults | |||
* Median age of 63 years old | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Smoking]], previous [[chemotherapy]] or [[radiation therapy]], [[myelodysplastic syndrome]], and exposure to the chemical [[benzene]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Fatigue]] | |||
* [[Bleeding]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Bone [[tenderness]] | |||
* [[Dyspnea]] | |||
* Leukemia cutis | |||
* Swelling of the [[Gingiva|gums]] | |||
* Chloroma | |||
* Rare LAP | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Anemia]] | |||
* [[Thrombocytopenia]] | |||
* [[Leukocytosis]] or [[leukopenia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Leukemic blasts | |||
* Positive [[Auer rod|Auer rods]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Flow cytometry]] > 20% blasts of [[myeloid]] lineage | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Persistent or frequent [[infections]] | |||
* Fatal within weeks or months if left untreated | |||
* [[Down syndrome]] or [[Bloom syndrome]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Acute lymphoblastic leukemia]]<ref name="pmid30302234">{{cite journal |vauthors=Sawalha Y, Advani AS |title=Management of older adults with acute lymphoblastic leukemia: challenges & current approaches |journal=Int J Hematol Oncol |volume=7 |issue=1 |pages=IJH02 |date=March 2018 |pmid=30302234 |pmc=6176956 |doi=10.2217/ijh-2017-0023 |url=}}</ref><ref name="pmid23841506">{{cite journal |vauthors=Portell CA, Advani AS |title=Novel targeted therapies in acute lymphoblastic leukemia |journal=Leuk. Lymphoma |volume=55 |issue=4 |pages=737–48 |date=April 2014 |pmid=23841506 |doi=10.3109/10428194.2013.823493 |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Arrest of [[lymphoblasts]] | |||
* Chromosomal translocations: t(9;22) , t(12;21), t(5;14), t(1;19) | |||
| align="left" style="background:#F5F5F5;" + | | |||
* The most common cancer in children | |||
*Peak 2-5 years of age | |||
*Boys > girls | |||
| align="left" style="background:#F5F5F5;" + | | |||
* History of [[cancer]] | |||
* History of drug exposure | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Generalized weakness | |||
* [[Fatigue]] | |||
* [[Bleeding]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Hepatosplenomegaly]] | |||
* LAP | |||
* [[Dyspnea]] | |||
* [[Pallor]] | |||
* [[Papilledema]] | |||
* [[Meningism|Nuchal rigidity]] | |||
* [[Cranial nerve palsy]] | |||
* [[Testicle|Testicular]] enlargement | |||
* [[Mediastinal mass]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Anemia]] | |||
* [[Thrombocytopenia]] | |||
* Normal or slightly increased [[White blood cells|WBC]] counts | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Lymphoblast|Lymphoblasts]] | |||
* Atypical cells | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Bone marrow examination|Bone marrow biopsy]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[CNS]] involvement | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Chronic myelogenous leukemia]]<ref name="pmid25814082">{{cite journal |vauthors=Saußele S, Silver RT |title=Management of chronic myeloid leukemia in blast crisis |journal=Ann. Hematol. |volume=94 Suppl 2 |issue= |pages=S159–65 |date=April 2015 |pmid=25814082 |doi=10.1007/s00277-015-2324-0 |url=}}</ref><ref name="pmid30285354">{{cite journal |vauthors=Eden RE, Coviello JM |title= |journal= |volume= |issue= |pages= |date= |pmid=30285354 |doi= |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Dysregulated production and uncontrolled proliferation of mature and maturing [[Granulocyte|granulocytes]] | |||
* [[BCR/ABL|BCR-ABL1]] fusion gene | |||
* [[Dominance relationship|Autosomal dominant]] mutation | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Median age 50 years old | |||
| align="center" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Generalized weakness | |||
* [[Fatigue]] | |||
* [[Satiety|Early satiety]] | |||
* Abdominal fullness | |||
* Bleeding | |||
| align="left" style="background:#F5F5F5;" + | | |||
*Asymptomatic | |||
*[[Blast crisis]] | |||
*Excessive [[Perspiration|sweating]] | |||
* [[Papilledema]] | |||
* [[Tenderness]] over the lower [[sternum]] | |||
* [[Hepatosplenomegaly]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Anemia]] | |||
* [[White blood cells|WBC]] > 100,000/microL | |||
* Absolute [[basophilia]] and [[eosinophilia]] | |||
* [[Platelet|Plt]] > 600,000 to 700,000/microL | |||
* Low [[leukocyte alkaline phosphatase]] | |||
* High [[uric acid]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* All cells of the neutrophilic series, from [[Myeloblast|myeloblasts]] to mature [[Neutrophil|neutrophils]] | |||
* [[Myelocyte]] bulge | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Bone marrow examination|Bone marrow biopsy]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Acute [[Gout|gouty arthritis]] | |||
* Venous obstruction | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |'''[[Chronic lymphocytic leukemia]]'''<ref name="pmid266906142">{{cite journal |vauthors=Rai KR, Jain P |title=Chronic lymphocytic leukemia (CLL)-Then and now |journal=Am. J. Hematol. |volume=91 |issue=3 |pages=330–40 |date=March 2016 |pmid=26690614 |doi=10.1002/ajh.24282 |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Progressive accumulation of monoclonal [[B cell|B lymphocytes]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* The most common leukemia in adults in western countries | |||
* M > F | |||
* Median age 70 years old | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Positive family history | |||
* Exposure to [[Herbicide|herbicides]] or [[Insecticide|insecticides]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Bleeding | |||
* Abdominal pain | |||
* Generalized [[weakness]] | |||
* [[Anorexia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* LAP (Most common sign) | |||
* [[Hepatosplenomegaly]] | |||
* [[Skin lesion|Skin lesions]] (leukemia cutis) | |||
* [[Sleep hyperhidrosis|Night sweats]] | |||
* [[Muscle wasting]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Anemia]] | |||
* [[Thrombocytopenia]] | |||
* Absolute [[lymphocytosis]] >5000 cells/μl | |||
* [[Neutropenia]] | |||
* Positive direct Coombs test | |||
* [[Hypogammaglobulinemia]] | |||
* Elevated [[lactate dehydrogenase]] and [[beta-2 microglobulin]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Presence of smudge cells | |||
* Monoclonality of [[Light chain|kappa]] and [[Lambda (anatomy)|lambda]] producing [[B cell|B cells]] | |||
* Express [[CD19]], [[CD20]], [[CD23]], and [[CD5]] on the [[cell]] surface | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Flow cytometry]] of the [[Venous blood|peripheral blood]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Extranodal involvement of [[skin]], [[kidney]], [[lung]], [[Spinal cord|spine]] | |||
* [[Membranoproliferative glomerulonephritis]] | |||
* [[Autoimmune hemolytic anemia]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]<ref name="pmid29110361">{{cite journal |vauthors=Troussard X, Cornet E |title=Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment |journal=Am. J. Hematol. |volume=92 |issue=12 |pages=1382–1390 |date=December 2017 |pmid=29110361 |pmc=5698705 |doi=10.1002/ajh.24936 |url=}}</ref><ref name="pmid29118233">{{cite journal |vauthors=Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H |title=Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology |journal=J Natl Compr Canc Netw |volume=15 |issue=11 |pages=1414–1427 |date=November 2017 |pmid=29118233 |doi=10.6004/jnccn.2017.0165 |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Accumulation of small mature [[B cell]] lymphoid cells with abundant [[cytoplasm]] and "hairy" projections | |||
* [[BRAF]] mutation | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Uncommon | |||
* Median age 50 to 55 years old | |||
* M >> F | |||
* More common in Caucasians than Blacks | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Exposures to [[ionizing radiation]], [[Pesticide|pesticides]], and farming | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Generalized weakness | |||
* [[Fatigue]] | |||
* [[Satiety|Early satiety]] | |||
* Abdominal fullness | |||
* Bleeding | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Asymptomatic | |||
* [[Splenomegaly]] | |||
* Spontaneous [[splenic rupture]] | |||
* [[Rash|Skin rash]] | |||
* [[Ascites]] | |||
* [[Pleural effusion]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Cytopenia]] | |||
* [[Leukocytosis]] in 10 to 20 percent | |||
* [[Azotemia]] | |||
* Abnormal [[liver function tests]] | |||
* [[Hypergammaglobulinemia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Pancytopenia]] with [[monocytopenia]] and circulating tumor cells characteristic of HCL | |||
* Dry [[bone marrow]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Analysis of [[Venous blood|peripheral blood]] + [[immunophenotyping]] by [[flow cytometry]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Vasculitis]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |Large granular lymphocytic leukemia<ref name="pmid28128670">{{cite journal |vauthors=Matutes E |title=Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options |journal=Expert Rev Hematol |volume=10 |issue=3 |pages=251–258 |date=March 2017 |pmid=28128670 |doi=10.1080/17474086.2017.1284585 |url=}}</ref><ref name="pmid28717070">{{cite journal |vauthors=Oshimi K |title=Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias |journal=Intern. Med. |volume=56 |issue=14 |pages=1759–1769 |date=2017 |pmid=28717070 |pmc=5548667 |doi=10.2169/internalmedicine.56.8881 |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Clonal proliferation of cytotoxic T cells | |||
* Dysregulation of apoptosis through abnormalities in the Fas/Fas ligand pathway | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Rare | |||
* Median age 60 years | |||
* M = F | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Autoimmune diseases | |||
* Lymphoproliferative disorders | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Generalized weakness | |||
* [[Fatigue]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Mostly asymptomatic | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Modest [[lymphocytosis]] | |||
* [[Neutropenia]] | |||
* [[Anemia]] | |||
* [[Thrombocytopenia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Large lymphocytes with a condensed round or oval nucleus, abundant pale basophilic cytoplasm, and small azurophilic granules | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Biopsy and flow cytometry + T-cell receptor gene rearrangement studies | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Recurrent bacterial infection | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Chronic neutrophilic leukemia]]<ref name="pmid29512199">{{cite journal |vauthors=Elliott MA, Tefferi A |title=Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management |journal=Am. J. Hematol. |volume=93 |issue=4 |pages=578–587 |date=August 2018 |pmid=29512199 |doi=10.1002/ajh.24983 |url=}}</ref> | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Mature granulocytic proliferation in the blood and marrow | |||
* Point mutations in the CSF3R gene | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Very rare | |||
* M = F | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Multiple myeloma]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Generalized weakness | |||
* [[Fatigue]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Hepatosplenomegaly]] | |||
* Pruritus | |||
* Gout | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Peripheral blood neutrophilia (> 25 x 10<sup>9</sup>/L) with myeloid precursors (promyelocytes, myelocytes, metamyelocytes) | |||
* Elevated [[leukocyte alkaline phosphatase]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Toxic granulation in the [[Neutrophil|neutrophils]] | |||
* Nuclear hypersegmentation | |||
* Increased myeloid:erythroid ratio > 20:1 | |||
| align="left" style="background:#F5F5F5;" + | | |||
* WHO diagnostic criteria include leukocytosis of ≥ 25 x 109/L | |||
* More than 80% neutrophils, | |||
* Less than 10% circulating neutrophil precursors with blasts | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Poor prognosis | |||
* Absence of the Philadelphia chromosome or a BCR/ABL fusion gene | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Chronic eosinophilic leukemia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Constitutional | |||
* [[Rash]] | |||
* [[Rhinitis]] | |||
* [[Gastritis]] | |||
* [[Thromboembolism]]<nowiki/>related | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Hypertension]] | |||
* [[Eczema]], [[mucosal]][[ulcers]], [[erythema]] | |||
* [[Angioedema]] | |||
* [[Ataxia]] | |||
* [[Anemia]] | |||
* [[Lymphadenopathy]] | |||
* [[Hepatosplenomegaly]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
*[[Leukocytosis]] with left shift | |||
*[[Eosinophilia]] | |||
*[[Basophilia]] | |||
*[[Monocytosis]] | |||
*[[Anemia]] | |||
*[[Thrombocytopenia]] | |||
*↑ [[B12]] levels | |||
*↑ [[LDH]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* Hypercelluar with ↑ [[eosinophilic]]<nowiki/>precursors, ↑ [[eosinophils]], and atypical [[mononuclear cells]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
*[[Heart failure]] [[Lung fibrosis]] | |||
*[[Encephalopathy]] | |||
*[[Erythema annulare centrifugam]] | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Chronic monocytic leukemia electrocardiogram|Chronic monocytic leukemia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Prolymphocytic leukemia]] (PLL) | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[T-cell large granular lymphocyte leukemia|T-cell large granular lymphocytic leukemia]] (TLGL) | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Aggressive NK-cell leukemia]] (ANKL) | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Adult T-cell leukemia|Adult T-cell leukemia/lymphoma]] (ATLL) | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Sezary syndrome]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Myelodysplastic syndrome]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
*Constitutional symptoms | |||
*[[Bleeding]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
*[[Pallor]] | |||
*[[Petechiae]] | |||
*[[Organomegaly]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
* [[Pancytopenia]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
*Hypercellular/ normocellular [[bone marrow]] with [[Dysplastic change|dysplastic]] changes | |||
*Macro-ovalocytes | |||
*Basophilic stippling | |||
*[[Howell-Jolly body]] | |||
| align="left" style="background:#F5F5F5;" + |Biopsy | |||
| align="left" style="background:#F5F5F5;" + | | |||
*[[Leukemia]] transformation | |||
*Acquired pseudo-Pelger-Huët anomaly | |||
*Infection | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Myeloproliferative disorders]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|- | |||
! align="center" style="background:#DCDCDC;" + |[[Leukemoid reaction]] | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
| align="left" style="background:#F5F5F5;" + | | |||
|} | |} | ||
Latest revision as of 22:42, 28 March 2019
Prolymphocytic leukemia Main page |
Differentiating B-cell prolymphocytic leukemia from T-cell prolymphocytic leukemia |
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Carlos A Lopez, M.D. [2], Maria Fernanda Villarreal, M.D. [3]
For more information regarding B-cell prolymphocytic leukemia, please click here.
For more information regarding T-cell prolymphocytic leukemia, please click here.
Overview
Prolymphocytic leukemia is a rare lymphoid leukemia, which account for only about 2% of all mature lymphoid leukemias. Prolymphocytic leukemias present similar to leukemia. Like lymphomas, they originate in the lymphocytes, but do not form solid tumors. Prolymphocytic leukemias are also considered lymphoproliferative disorders, which lymphocytes are produced in large amounts. Prolymphocytic leukemia may be classified according to the type of cell involved: B-cell prolymphocytic leukemia and T-cell prolymphocytic leukemia. Originally, it was thought to be a rare variation of chronic lymphocytic leukemia, but is now considered a distinct disease. It is usually classified as a kind of chronic lymphocytic leukemia. Although these 2 types of prolymphocytic leukemias share some of the same characteristics, the World Health Organization (WHO) classifies them as different types of lymphoid leukemias.[1]
Classification
For more details about each specific type of prolymphocytic leukemia, please select:
Prolymphocytic leukemia | |||||||||||||||||||||
B-cell prolymphocytic leukemia | T-cell prolymphocytic leukemia | ||||||||||||||||||||
Differentiating B-Prolymphocytic Leukemia from T-Prolymphocytic Leukemia
In order to distinguish B-prolymphocytic leukemia from T-prolymphocytic leukemia, see the table below.
Characteristics | B-cell Prolymphocytic Leukemia | T-cell Prolymphocytic Leukemia |
---|---|---|
Epidemiology |
|
|
Age |
|
|
Onset |
|
|
Clinical Features |
B symptoms
|
|
Diagnosis | Peripheral blood smear
Biomarkers
|
Peripheral blood smear
Biomarkers
|
Differentiating Prolymphocytic Leukemia from other Leukemias
Differential Diagnosis | Surface Immunoglobulin | CD5 | CD22/FMC7 | CD23 | CD79b | CD103 |
---|---|---|---|---|---|---|
Prolymphocytic leukaemia | Strongly positive | Negative | Positive | Negative | Positive | Negative |
Hairy cell leukaemia | Strongly positive | Negative | Positive | Negative | Positive/Negative | Positive |
Chronic lymphocytic leukaemia | Weakly positive | Positive | Negative | Positive | Negative | Positive/Negative |
Mantle cell lymphoma | Positive | Positive | Strongly positive | Negative | Strongly positive | Negative |
Follicular lymphoma | Strongly positive | Negative | Positive | Negative | Strongly positive | Negative |
Disease | Etiology | Clinical Manifestation | Laboratory Findings | Gold standard diagnosis | Associated findings | ||||
---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | Lab | Histopathology | ||||
Acute myelogenous leukemia[2][3] |
|
|
|
|
|
|
| ||
Acute lymphoblastic leukemia[4][5] |
|
|
|
|
|
| |||
Chronic myelogenous leukemia[6][7] |
|
|
|
|
|
|
| ||
Disease | Etiology | Demography | History | Symptoms | Signs | Lab | Histopathology | Gold standard diagnosis | Associated findings |
Chronic lymphocytic leukemia[8] |
|
|
|
|
|
|
| ||
Hairy cell leukemia[9][10] |
|
|
|
|
|
|
|
||
Large granular lymphocytic leukemia[11][12] |
|
|
|
|
|
|
|
| |
Chronic neutrophilic leukemia[13] |
|
|
|
|
|
|
|
| |
Disease | Etiology | Demography | History | Symptoms | Signs | Lab | Histopathology | Gold standard diagnosis | Associated findings |
Chronic eosinophilic leukemia |
|
|
|
||||||
Chronic monocytic leukemia | |||||||||
Prolymphocytic leukemia (PLL) | |||||||||
T-cell large granular lymphocytic leukemia (TLGL) | |||||||||
Disease | Etiology | Demography | History | Symptoms | Signs | Lab | Histopathology | Gold standard diagnosis | Associated findings |
Aggressive NK-cell leukemia (ANKL) | |||||||||
Adult T-cell leukemia/lymphoma (ATLL) | |||||||||
Sezary syndrome | |||||||||
Myelodysplastic syndrome |
|
|
Biopsy |
| |||||
Myeloproliferative disorders | |||||||||
Leukemoid reaction |
References
- ↑ "World Health Organization".
- ↑ Saif A, Kazmi S, Naseem R, Shah H, Butt MO (August 2018). "Acute Myeloid Leukemia: Is That All There Is?". Cureus. 10 (8): e3198. doi:10.7759/cureus.3198. PMID 30410824. Vancouver style error: initials (help)
- ↑ Estey EH (April 2013). "Acute myeloid leukemia: 2013 update on risk-stratification and management". Am. J. Hematol. 88 (4): 318–27. doi:10.1002/ajh.23404. PMID 23526416.
- ↑ Sawalha Y, Advani AS (March 2018). "Management of older adults with acute lymphoblastic leukemia: challenges & current approaches". Int J Hematol Oncol. 7 (1): IJH02. doi:10.2217/ijh-2017-0023. PMC 6176956. PMID 30302234.
- ↑ Portell CA, Advani AS (April 2014). "Novel targeted therapies in acute lymphoblastic leukemia". Leuk. Lymphoma. 55 (4): 737–48. doi:10.3109/10428194.2013.823493. PMID 23841506.
- ↑ Saußele S, Silver RT (April 2015). "Management of chronic myeloid leukemia in blast crisis". Ann. Hematol. 94 Suppl 2: S159–65. doi:10.1007/s00277-015-2324-0. PMID 25814082.
- ↑ Eden RE, Coviello JM. PMID 30285354. Missing or empty
|title=
(help) - ↑ Rai KR, Jain P (March 2016). "Chronic lymphocytic leukemia (CLL)-Then and now". Am. J. Hematol. 91 (3): 330–40. doi:10.1002/ajh.24282. PMID 26690614.
- ↑ Troussard X, Cornet E (December 2017). "Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment". Am. J. Hematol. 92 (12): 1382–1390. doi:10.1002/ajh.24936. PMC 5698705. PMID 29110361.
- ↑ Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H (November 2017). "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology". J Natl Compr Canc Netw. 15 (11): 1414–1427. doi:10.6004/jnccn.2017.0165. PMID 29118233.
- ↑ Matutes E (March 2017). "Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options". Expert Rev Hematol. 10 (3): 251–258. doi:10.1080/17474086.2017.1284585. PMID 28128670.
- ↑ Oshimi K (2017). "Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias". Intern. Med. 56 (14): 1759–1769. doi:10.2169/internalmedicine.56.8881. PMC 5548667. PMID 28717070.
- ↑ Elliott MA, Tefferi A (August 2018). "Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management". Am. J. Hematol. 93 (4): 578–587. doi:10.1002/ajh.24983. PMID 29512199.